Schizophrenia - Pipeline Review, H1 2018; New Report Launched has announced the addition of “Schizophrenia - Pipeline Review, H1 2018” research report to their website


Bangalore, India -- (SBWire) -- 06/29/2018 --Schizophrenia - Pipeline Review, H1 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights
Schizophrenia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 12, 12, 16, 1, 59, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 2 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 334 pages "Schizophrenia - Pipeline Review, H1 2018" report covers Introduction, Schizophrenia - Overview, Schizophrenia - Therapeutics Development, Schizophrenia - Therapeutics Assessment, Schizophrenia - Companies Involved in Therapeutics Development, Schizophrenia - Drug Profiles, Schizophrenia - Dormant Projects,Appendix. This report Covered Companies few are - Avanir Pharmaceuticals Inc, Avineuro Pharmaceuticals Inc, BCWorld Pharm Co Ltd, Bioblue Technologies Inc, BioCrea GmbH, BioHealthonomics Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Concert Pharmaceuticals Inc, Curemark LLC, Daewoong Pharmaceutical Co Ltd.

For more information Visit at:

Find all Pharma and Healthcare Reports at -

Related Reports;

Binge Eating Disorder - Pipeline Review, H1 2018 - Visit at -

Gastroenteritis - Pipeline Review, H1 2018 - Visit at -

About is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Media Relations Contact

Sudeep Chakravarty
Director - Operations

View this press release online at: